Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma

Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient's treatment options. MEK inhibitors have demonstrated little efficacy in patients with NRAS‐mutated melanoma owing to primary and secondary resistance. We repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Matter, Alexandra Valeska, Micaletto, Sara, Urner‐Bloch, Ursula, Dummer, Reinhard, Goldinger, Simone M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648363/
https://www.ncbi.nlm.nih.gov/pubmed/32886824
http://dx.doi.org/10.1634/theoncologist.2019-0656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648363/
https://www.ncbi.nlm.nih.gov/pubmed/32886824
http://dx.doi.org/10.1634/theoncologist.2019-0656

Ejemplares similares